PARIS, January 06, 2025–(BUSINESS WIRE)–Regulatory News:
ACTICOR BIOTECH (FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, announced today that the Paris Commercial Court, has declared on January 2, the company in liquidation proceedings.
The liquidator is Marc-Antoine Rey, SELARL BDR & Associés, 34 rue Sainte Anne, 75001 Paris, [email protected]
In view of this decision by the Paris Commercial Court, Acticor Biotech shares will not be listed again, and Euronext will shortly be asked to delist them.
Dr Gilles Avenard has published a letter to shareholders available on the Company’s website: www.acticor-biotech.com